Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those wh...
Guardado en:
Autores principales: | , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1f0be989ac644ef1b055811f264ef492 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:1f0be989ac644ef1b055811f264ef492 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:1f0be989ac644ef1b055811f264ef4922021-11-11T15:33:38ZMolecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review10.3390/cancers132154772072-6694https://doaj.org/article/1f0be989ac644ef1b055811f264ef4922021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5477https://doaj.org/toc/2072-6694Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those who do might have significant advantages in terms of survival rates. Breast cancer (BC) is a heterogeneous disease that requires personalized treatment strategies. The development of targeted therapies depends on identifying biomarkers that can be used to assess treatment efficacy as well as the discovery of new and more accurate therapeutic agents. With the development of new “OMICS” technologies, i.e., genomics, transcriptomics, and proteomics, among others, the discovery of new biomarkers is increasingly being used in the context of clinical practice, bringing us closer to personalized management of BC treatment. The aim of this review is to compile the main biomarkers that predict pCR in BC after NAC.Ana Julia Aguiar de FreitasRhafaela Lima CausinMuriele Bertagna VaruzzaCassio Murilo Trovo Hidalgo FilhoVinicius Duval da SilvaCristiano de Pádua SouzaMárcia Maria Chiquitelli MarquesMDPI AGarticlepathological complete responseneoadjuvant chemotherapybreast cancermolecular biomarkersNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5477, p 5477 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
pathological complete response neoadjuvant chemotherapy breast cancer molecular biomarkers Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 |
spellingShingle |
pathological complete response neoadjuvant chemotherapy breast cancer molecular biomarkers Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Ana Julia Aguiar de Freitas Rhafaela Lima Causin Muriele Bertagna Varuzza Cassio Murilo Trovo Hidalgo Filho Vinicius Duval da Silva Cristiano de Pádua Souza Márcia Maria Chiquitelli Marques Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review |
description |
Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those who do might have significant advantages in terms of survival rates. Breast cancer (BC) is a heterogeneous disease that requires personalized treatment strategies. The development of targeted therapies depends on identifying biomarkers that can be used to assess treatment efficacy as well as the discovery of new and more accurate therapeutic agents. With the development of new “OMICS” technologies, i.e., genomics, transcriptomics, and proteomics, among others, the discovery of new biomarkers is increasingly being used in the context of clinical practice, bringing us closer to personalized management of BC treatment. The aim of this review is to compile the main biomarkers that predict pCR in BC after NAC. |
format |
article |
author |
Ana Julia Aguiar de Freitas Rhafaela Lima Causin Muriele Bertagna Varuzza Cassio Murilo Trovo Hidalgo Filho Vinicius Duval da Silva Cristiano de Pádua Souza Márcia Maria Chiquitelli Marques |
author_facet |
Ana Julia Aguiar de Freitas Rhafaela Lima Causin Muriele Bertagna Varuzza Cassio Murilo Trovo Hidalgo Filho Vinicius Duval da Silva Cristiano de Pádua Souza Márcia Maria Chiquitelli Marques |
author_sort |
Ana Julia Aguiar de Freitas |
title |
Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review |
title_short |
Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review |
title_full |
Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review |
title_fullStr |
Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review |
title_full_unstemmed |
Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review |
title_sort |
molecular biomarkers predict pathological complete response of neoadjuvant chemotherapy in breast cancer patients: review |
publisher |
MDPI AG |
publishDate |
2021 |
url |
https://doaj.org/article/1f0be989ac644ef1b055811f264ef492 |
work_keys_str_mv |
AT anajuliaaguiardefreitas molecularbiomarkerspredictpathologicalcompleteresponseofneoadjuvantchemotherapyinbreastcancerpatientsreview AT rhafaelalimacausin molecularbiomarkerspredictpathologicalcompleteresponseofneoadjuvantchemotherapyinbreastcancerpatientsreview AT murielebertagnavaruzza molecularbiomarkerspredictpathologicalcompleteresponseofneoadjuvantchemotherapyinbreastcancerpatientsreview AT cassiomurilotrovohidalgofilho molecularbiomarkerspredictpathologicalcompleteresponseofneoadjuvantchemotherapyinbreastcancerpatientsreview AT viniciusduvaldasilva molecularbiomarkerspredictpathologicalcompleteresponseofneoadjuvantchemotherapyinbreastcancerpatientsreview AT cristianodepaduasouza molecularbiomarkerspredictpathologicalcompleteresponseofneoadjuvantchemotherapyinbreastcancerpatientsreview AT marciamariachiquitellimarques molecularbiomarkerspredictpathologicalcompleteresponseofneoadjuvantchemotherapyinbreastcancerpatientsreview |
_version_ |
1718435164656238592 |